
|Articles|July 1, 2007
- Volume 0 0
Update on Investigational Alzheimer's Drug
Author(s)Susan Farley
Advertisement
Voyager Pharmaceutical Corp recently informed its shareholders of preliminary results from a trial of an investigational drug to treat Alzheimer's disease (AD). The researchers studying the drug, Memryte, observed positive effects among women but not among men.
The findings have prompted Voyager to focus on developing the drug to treat AD specifically for women.
Articles in this issue
almost 19 years ago
pharmacy TECHNOLOGY newsalmost 19 years ago
pharmacy TECHNOLOGY productsalmost 19 years ago
health-systems PRODUCT newsalmost 19 years ago
generic times product newsalmost 19 years ago
can you READ these Rxs?almost 19 years ago
A closer look at new FDA actionsalmost 19 years ago
can you READ these Rxs?almost 19 years ago
compounding HOTLINEalmost 19 years ago
Is There Science in Quality?almost 19 years ago
Vaccines: Are You Protected?Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Factors Associated With GLP-1 RA Nonresponse in T2D—and What Pharmacists Should Screen For
2
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
3
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says
4
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
5






































































































































